-
EP3082760
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3082760
| EP3082760 - LEPTIN mRNA COMPOSITIONS AND FORMULATIONS [Right-click to bookmark this link] | Status | The application has been withdrawn Status updated on 16.06.2017 Database last updated on 24.08.2024 | Most recent event Tooltip | 16.06.2017 | Withdrawal of application | published on 19.07.2017 [2017/29] | Applicant(s) | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | [2016/43] | Inventor(s) | 01 /
BYERS, Crystal Novartis Institutes for BioMedical Research Inc. 100 Technology Square Cambridge, Massachusetts 02139 / US | 02 /
CAPLAN, Shari Lynn Novartis Institutes for BioMedical Research Inc. 100 Technology Square Cambridge, Massachusetts 02139 / US | 03 /
GAMBER, Gabriel Grant Novartis Institutes for BioMedical Research Inc. 400 Technology Square Cambridge, Massachusetts 02139 / US | 04 /
HAHM, Seung Novartis Institutes for BioMedical Research Inc. 100 Technology Square Cambridge, Massachusetts 02139 / US | 05 /
HELDWEIN, Kurt Alex Novartis Institutes for BioMedical Research Inc. 100 Technology Square Cambridge, Massachusetts 02139 / US | 06 /
SPLAWSKI, Igor Novartis Institutes for BioMedical Research Inc. 100 Technology Square Cambridge, Massachusetts 02139 / US | 07 /
ZABAWA, Thomas Novartis Institutes for BioMedical Research Inc. 100 Technology Square Cambridge, Massachusetts 02139 / US | 08 /
ZECRI, Frédéric Novartis Institutes for BioMedical Research Inc. 100 Technology Square Cambridge, Massachusetts 02139 / US | [2016/43] | Representative(s) | Fredh, Fredrik, et al Novartis Pharma AG Patent Department Postfach 4002 Basel / CH | [2016/43] | Application number, filing date | 14824309.0 | 17.12.2014 | [2016/43] | WO2014US70896 | Priority number, date | US201361918161P | 19.12.2013 Original published format: US 201361918161 P | US201461933964P | 31.01.2014 Original published format: US 201461933964 P | [2016/43] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2015095351 | Date: | 25.06.2015 | Language: | EN | [2015/25] | Type: | A1 Application with search report | No.: | EP3082760 | Date: | 26.10.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.06.2015 takes the place of the publication of the European patent application. | [2016/43] | Search report(s) | International search report - published on: | EP | 25.06.2015 | Classification | IPC: | A61K9/00, A61K38/00, A61K47/48, A61K9/14, A61K9/51, A61K31/00 | [2016/43] | CPC: |
A61K38/2264 (EP,US);
A61K31/7105 (EP,US);
A61K47/543 (EP,US);
A61K48/0025 (EP,US);
A61K48/005 (EP,US);
A61K48/0075 (EP,US);
A61K48/0091 (EP,US);
A61K9/0019 (EP,US);
A61K9/1617 (US);
A61K9/1641 (US);
A61K9/5123 (EP,US);
A61P3/04 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/43] | Title | German: | LEPTIN-MRNA-ZUSAMMENSETZUNGEN UND -FORMULIERUNGEN | [2016/43] | English: | LEPTIN mRNA COMPOSITIONS AND FORMULATIONS | [2016/43] | French: | COMPOSITIONS ET FORMULATIONS D'ARNM DE LA LEPTINE | [2016/43] | Entry into regional phase | 19.07.2016 | National basic fee paid | 19.07.2016 | Designation fee(s) paid | 19.07.2016 | Examination fee paid | Examination procedure | 18.07.2016 | Amendment by applicant (claims and/or description) | 19.07.2016 | Examination requested [2016/43] | 12.06.2017 | Application withdrawn by applicant [2017/29] | Fees paid | Renewal fee | 13.12.2016 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XP]WO2014136086 (NOVARTIS AG [CH], et al) [XP] 1-3,7-36 * page 198, lines 18-29 *; | [I]WO2010142981 (BABRAHAM INST [GB], et al) [I] 1-36 * page 4, paragraph 2 * * page 14, paragraph 8 *; | [AD]US8278036 (KARIKO KATALIN [US], et al) [AD] 1-36 * the whole document *; | [A] - KARIKÓ KATALIN ET AL, "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 16, no. 11, doi:10.1038/MT.2008.200, ISSN 1525-0024, (20081101), pages 1833 - 1840, (20080916), XP002598556 [A] 1-36 * the whole document * DOI: http://dx.doi.org/10.1038/mt.2008.200 | by applicant | US8278036 | WO2011153493 | US2013102034 | US2013115272 | US2013123481 | WO2007036366 | WO9640062 | US5264221 | US5665710 | WO9704787 | US6011020 | US6074667 | US6110490 | US6147204 | US6271206 | US6312956 | US6465188 | US6506564 | US6750016 | US7112337 | WO2013090186 | US6835393 | US7374778 | US7737108 | US7718193 | US8003129 | EP1044021 | US6177274 | US2009042829 | US2009042825 | US2012004293 | US8236330 | US8246968 | WO2008103276 | US2010260817 | WO2011015862 | WO2012082574 | WO2012068187 | US6696038 | US2003073619 | US2004142474 | US2010004315 | US6517869 | US6267987 | US6652886 | US6217912 | US8057821 | US2012009145 | US2010004313 | WO2011076807 | WO2006007712 | US5735814 | US5814014 | US6042579 | US2011230839 | US2011172610 | US2011270184 | US2011218497 | US2010130910 | US2011196308 | US2003073908 | US7364568 | US7150726 | US7473247 | US6607513 | US6743211 | US4695273 | US3552394 | WO03094995 | WO2012006259 | US7699803 | US7998119 | US8007466 | - LICINIO J ET AL., PROC. NATL. ACAD. SCI. USA, (2004), vol. 101, no. 13, pages 4531 - 6 | - EBIHARA K ET AL., J. CLIN. ENDOCRINOL. METAB., (2007), vol. 92, pages 532 - 541 | - CHAN JL ET AL., ENDOCR. PRACT., (2011), vol. 17, no. 6, pages 922 - 932 | - KARIKO K ET AL., CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, (2007), vol. 10, no. 5, pages 523 - 532 | - KARIKO K ET AL., MOLECULAR THERAPY, (2008), vol. 16, no. 11, pages 1833 - 1840 | - ANDERSON BR ET AL., NUCLEIC ACIDS RES., (2010), vol. 38, no. 17, pages 5884 - 5892 | - LARKIN MA ET AL., "Clustal @ and Clustal X version 2.0.", BIOINFORMATICS, (2007), vol. 23, no. 21, pages 2947 - 2948 | - DOYON C ET AL., "Molecular Evolution of Leptin.", GEN. AND COMP. ENDOCRINOL., (2001), vol. 124, pages 188 - 198 | - DENVER RJ ET AL., "Evolution of Leptin Structure and Function.", NEUROENDOCRINOL, (2011), vol. 94, pages 21 - 38 | - HEN G ET AL., "Monitoring leptin activity using the chicken leptin receptor.", J. ENDOCRINOL., (2008), vol. 197, pages 325 - 333 | - ALLEN LV ET AL., Remington's The Science and Practice of Pharmacy, 22nd edition, PHARMACEUTICAL PRESS | - JOURNAL OF PHARMACEUTICAL SCIENCE, (1977), vol. 66, page 2 | - KELESIDIS T ET AL., ANNALS OF INTERNAL MEDICINE, (2010), vol. 152, no. 2, pages 93 - 101 | - DARDENO TA ET AL., FRONTIERS IN NEUROENDOCRINOLOGY, (2010), vol. 31, pages 377 - 393 | - RYDZIK AM ET AL., ORG. BIOMOL. CHEM., (2009), vol. 7, no. 22, pages 4763 - 76 | - KOWALSKA J ET AL., RNA, (2008), vol. 14, no. 6, pages 1119 - 1131 | - GRUDZIEN-NOGALSKA E ET AL., RNA, (2007), vol. 13, no. 10, pages 1745 - 1755 | - GRUDZIEN E ET AL., RNA, (2004), vol. 10, no. 9, pages 1479 - 1487 | - JEMIELITY J ET AL., RNA, (2003), vol. 9, no. 9, pages 1108 - 1122 | - STEPINSKI J ET AL., RNA, (2001), vol. 7, no. 10, pages 1486 - 1495 | - KARIKO K ET AL., IMMUNITY, (2005), vol. 23, pages 165 - 175 | - CHAPMAN KA; WELLS RD, "Bacteriophage T7 late promoters; construction and in vitro transcription properties of deletion mutants.", NUCLEIC ACIDS RESEARCH, (1982), vol. 10, no. 20, pages 6331 - 6340 | - SCHENBORN ET; MIERENDORF RC, "A novel transcription property of SP6 and T7 RNA polymerases: dependence on template structure.", NUCIEICACIDS RESEARCH, (1985), vol. 13, no. 17, pages 6223 - 6236 | - LBACH J ET AL., "Identification of a T7 RNA polymerase variant that permits the enzymatic synthesis of fully 2'-O-methyl-modified mRNA.", J. BIOTECHNOLOGY, (2013), vol. 167, doi:doi:10.1016/j.jbiotec.2013.07.005, pages 287 - 295, XP028703516 DOI: http://dx.doi.org/10.1016/j.jbiotec.2013.07.005 | - KIM SH ET AL., JOURNAL OF CONTROLLED RELEASE, (2008), vol. 129, no. 2, pages 107 - 116 | - SORENSEN DR ET AL., J. MOL. BIOL., (2003), vol. 327, pages 761 - 766 | - VERMA UN ET AL., CLIN. CANCER RES., (2003), vol. 9, pages 1291 - 1300 | - ARNOLD AS ET AL., J. HYPERTENS., (2007), vol. 25, pages 197 - 205 | - NGUYEN J; SZOKA FC, ACCOUNTS OF CHEMICAL RESEARCH, (2012), vol. 45, no. 7, pages 1153 - 1162 | - BANERJEE ET AL., MED. CHEM., (1999), vol. 42, pages 4292 - 99 | - GODBEY ET AL., GENE THER., (1999), vol. 6, pages 1380 - 88 | - KICHLER ET AL., GENE THER., (1998), vol. 5, pages 855 - 60 | - BIRCHAA ET AL., J. PHARM., (1999), vol. 183, pages 195 - 207 | - DEFOUGEROLLES, HUM GENE THER., (2008), vol. 19, pages 125 - 132 | - ROZEMA ET AL., PROC. NATL. ACAD. SCI. USA, (2007), vol. 104, pages 12982 - 12887 | - HU-LIESKOVAN ET AL., CANCER RES., (2005), vol. 65, pages 8984 - 8982 | - HEIDEL ET AL., PROC. NATL. ACAD. SCI. USA, (2007), vol. 104, pages 5715 - 21 | - BENOIT ET AL., BIOMACROMOLECULES, (2011), vol. 12, pages 2708 - 2714 | - DAVIS, MOL. PHARM., (2009), vol. 6, pages 659 - 668 | - DAVIS, NATURE, (2010), vol. 464, pages 1067 - 1070 | - BOSE S ET AL., J. VIROL., (2004), vol. 78, page 8146 | - DONG Y ET AL., BIOMATERIALS, (2005), vol. 26, page 6068 | - LOBENBERG R ET AL., J DRUG TARGET, (1998), vol. 5, page 171 | - SAKUMA SR ET AL., INT. J. PHARM., (1999), vol. 177, page 161 | - VIROVIC L ET AL., EXPERT OPIN. DRUG DELIV., (2005), vol. 2, page 707 | - ZIMMERMANN E ET AL., EUR. J. PHARM. BIOPHARM., (2001), vol. 52, page 203 | - AKHTAR ET AL., TRENDS CELL BIOL., (1992), vol. 2, page 139 | - XU ET AL., BIOCHEMISTRY, (1996), vol. 35, page 5616 | - SEMPLE SC ET AL., NATURE BIOTECHNOL., (2010), vol. 28, no. 2, pages 172 - 176 | - JAYARAMAN M ET AL., ANGEW. CHEMIE INT. ED., (2012), vol. 51, pages 1 - 6 | - GALLAS A ET AL., CHEM. SOC. REV., (2013), vol. 42, pages 7983 - 7997 | - ROMBERG ET AL., PHARMACEUTICAL RESEARCH, (2008), vol. 25, no. 1, pages 55 - 71 | - HOEKSTRA ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, (2004), vol. 1660, pages 41 - 52 | - G. S. BANKER, Modern Pharmaceutics, Drugs and the Pharmaceutical Sciences, MARCEL DEKKER, NEW YORK, INC, (1996), vol. 72 | - WONG; NEUMANN, BIOCHEM. BIOPHYS. RES. COMMUN., (1982), vol. 107, pages 584 - 87 | - ORAL EA ET AL., ENGL. J. MED., (2002), vol. 346, no. 8, pages 570 - 8 | - JUGE-AUBRY CE; MEIER CA, MOL. CELL ENDOCRINOL., (2002), vol. 194, no. 1-2, pages 1 - 7 |